Publications

Seven Oaks Hospital has developed a rich culture of curiosity, ideation, and the collective determination to discover and deploy better ways of doing things. Today, world-leading researchers are drawn to the Seven Oaks Hospital community of innovation, and the momentum continues to build.

Publication

Intradialytic exercise preconditioning: an exploratory study on the effect on myocardial stunning

Penny, J, Salerno, F, Brar, R, Garcia, E, Rossum, K, McIntytre, C, Bohm, C.

Nephrology Dialysis Transplantation

Publication Category

Study Description

Exercise preconditioning provides immediate protection against cardiac ischemia in clinical/preclinical studies in subjects without chronic kidney disease. In individuals requiring renal replacement therapy, hemodialysis (HD) results in significant circulatory stress, causing acute ischemia with resultant recurrent and cumulative cardiac injury (myocardial stunning). Intradialytic exercise (IDE) has been utilized to improve functional status in individuals receiving HD. The objective of this study was to explore the role of IDE as a preconditioning intervention and assess its effect on HD-induced myocardial stunning.

Publication

The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease

Whitlock, R, Leslie, W, Shaw, J, Rigatto, C, Thorlacius, L, Komenda, P, Collister, D, Kanis, J, Tangri, N.

Kidney International

Publication Category

Study Description

The Fracture Risk Assessment Tool (FRAX®) was developed to predict fracture risk in the general population, but its applicability to patients with chronic kidney disease (CKD) is unknown. Using the Manitoba Bone Mineral Density (BMD) Database, we identified adults not receiving dialysis with available serum creatinine measurements and bone densitometry within 1 year. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Incident major osteoporotic fractures and hip fractures were ascertained from population-based health care databases. The performance of FRAX, derived without and with BMD, was studied in relation to CKD stage. Among 10,099 subjects (mean age 64 ± 13 years, 13.0% male), 2,154 had eGFR 30-60 mL/min/1.73 m2 (CKD stage 3) and 590 had eGFR <30 mL/min/1.73 m2 (CKD stages 4-5). During a 5-year observation period, 772 individuals experienced a major osteoporotic fracture and 226 had a hip fracture. FRAX predicted risk for major osteoporotic fracture and hip fracture in all eGFR strata. For every standard deviation increase in FRAX score derived with BMD, the hazard ratio (HR) for hip fracture was 4.54 (95% confidence interval [CI] 3.57-5.77) in individuals with eGFR ? 60 mL/min/1.73m2, 4.52 (95% CI 3.15-6.49) in individuals with eGFR 30-60 mL/min/1.73m2, and 3.10 (95% CI 1.80-5.33) in individuals with eGFR <30 mL/min/1.73m2. The relationship between FRAX and major osteoporotic fracture was stronger in those with CKD compared to those with preserved eGFR. These findings support the use of FRAX to risk stratify patients with non-dialysis CKD for major osteoporotic fractures and hip fractures.

Publication

A Passive Mixing Microfluidic Urinary Albumin Chip for Chronic Kidney Disease Assessment

Wu, J, Tomsa, D, Zhang, M, Komenda, P, Tangri, N, Rigatto, C, Lin, F.

ACS Sensors

Publication Category

Study Description

Urinary albumin level is an important indicator of kidney damage in chronic kidney disease (CKD) but effective routine albumin detection tools are lacking. In this paper, we developed a low-cost and high accuracy microfluidic urinary albumin chip (UAL-Chip) to rapidly measure albumin in urine. The UAL-Chip offers three major features: (1) we incorporated a fluorescent reaction assay into the chip to improve the detection accuracy; (2) we constructed a passive and continuous mixing module in the chip that provides user-friendly operation and greater signal stability; (3) we applied a pressure-balancing strategy based on the immiscible oil coverage that achieves precise control of the sample-dye mixing ratio. We validated the UAL-Chip using both albumin standards and urine samples from 12 CKD patients and achieved an estimated limit of detection (LOD) of 5.2 ?g/mL. The albumin levels in CKD patients’ urine samples measured by UAL-Chip is consistent with the traditional well-plate measurements and clinical results. We foresee the potential of extending this passive and precise mixing platform to assess various disease biomarkers.

Research Division · Seven Oaks Chronic Disease Innovation Centre
2300 McPhillips Street · Winnipeg, Manitoba · R2V 3M3 · 204‑631‑3834